Articles

Find an Article

Filter articles

Applied Filters

Showing 41 to 50 of 136 results

LSIPR 50 2017: Jane Philpott

Canada10-11-2017

Jane Philpott was selected in the LSIPR 50 2017 publication for​ ​her influence on the life sciences industry. She featured in the government and policy​ ​section, as LSIPR reports.

LSIPR 50 2017: Galit Gonen

UK10-11-2017

Galit Gonen was selected in the LSIPR 50 2017 publication for​ ​her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.

Data analysis: the highs and lows of generic-filed IPRs

US30-08-2017Wenhua Yu, Stephen Maebius and Tianran Yan

Inter partes reviews filed by generic drug companies have a higher institution rate but lower invalidation rate compared to other IPRs, say Wenhua Yu, Stephen Maebius and Tianran Yan of Foley & Lardner.

New framework for Spanish patentees

Spain28-06-2017

Spain’s new patent law came into force on April 1, and it contains a few measures which will affect pharmaceutical companies, says Dámaso Gallardo of Clarke Modet & Co.

The challenges of patenting cell therapies

International22-12-2016Glyn Truscott

A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains.

IP and investment: put your money where your mouth is

EU24-11-2016Dimitar Georgiev

Intellectual property in the life sciences arena can be an attractive investment target, but a long process of evaluation must take place first, cautions Dimitar Georgiev, founder and CEO of Paralax Life Sciences.

IP Life Sciences Exchange: a preview

Germany07-11-2016

The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.

Brexit: a fresh start for SPCs?

EU, UK20-10-2016Paul England and Matthew Royle

The UK’s vote to leave the EU may allow Britain to replace the SPC regulation—an often-criticised piece of law—and take a fresh approach to the system governing these rights, say Paul England and Matthew Royle of Taylor Wessing.

Pay-for-delay: Play by the rules

EU14-10-2016Bernd Allekotte and Franz Zimmer

The EU General Court’s decision in September to fine Lundbeck nearly €150 million over several pay-for-delay deals will encourage the European Commission to take further action against similar agreements, say Bernd Allekotte and Franz Zimmer of Grünecker.

The post-Brexit picture for orphan drugs

EU, UK13-10-2016Kei Enomoto

The UK government must ensure that the vital market for orphan drugs will continue to prosper following Brexit, says Kei Enomoto of Maucher Jenkins.

Showing 41 to 50 of 136 results

LSIPR